Sunday, November 03, 2013 4:27:02 PM
Based on the clinical work to date between oncs, ino and others using different ep devices, my opinion is that the 2007 piii failure had more to do with what they were delivering (the antibiotic bleomycin) than the ep tech itself. The interleukin used in the current trials is not a mere antibiotic (it regulates communication between cells) and does have a long track record of having some efficacy treating cancer. The problem with systemic delievery of interleukin is very nasty adverse effects. If the use of ep to deliver it locally rather than systemically can avoid AE's as much as has been suggested by the early data to date, without reducing its previous effiacy, then the stock should do quite well compared to current levels.
Long run, imo, it does not have nearly potential of ino, but is worth buying a few shares at the current bargain price.
Again, in case I didn't say it enough yet, this is just my opinion.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM